Historical reflections on cell culture engineering.
Cell culture engineering has enabled the commercial marketing of about a dozen human therapeutic products derived from rDNA technology and numerous monoclonal antibody products as well. A variety of technologies have proven useful in bringing products to the marketplace. Comparisons of the technologies available 15 years ago are contrasted with those available today. A number of improvements in unit operations have greatly improved the robustness of the processes during the past 15 years. Further evolution of the technology is expected in several directions driven by commercial and regulatory pressures. Some problems remain for the next generation of cell culture engineers to solve.
Lubiniecki
A S
AS
SmithKline Beecham Pharmaceuticals, Biopharmaceutical Development, 709 Swedeland Road, King of Prussia, PA, 19406-0939, U.S.A.